Veraxa Biotech Holding AG (FRA:J8L0) Other Current Liabilities: €2.66 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8L0 Veraxa Biotech Holding AG FRA:J8L0
13 GF Score
Price €1.62
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Other Current Liabilities?

Veraxa Biotech Holding AG FRA:J8L0 -2.06% 13 Other Current Liabilities is €2.66 Mil as of Dec. 2025. GuruFocus rates FRA:J8L0 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Veraxa Biotech Holding AG's other current liabilities for the quarter that ended in Dec. 2025 was €2.66 Mil.

Veraxa Biotech Holding AG's quarterly other current liabilities declined from Dec. 2024 (€1.18 Mil) to Jun. 2025 (€0.90 Mil) but then increased from Jun. 2025 (€0.90 Mil) to Dec. 2025 (€2.66 Mil).

Veraxa Biotech Holding AG's annual other current liabilities increased from Dec. 2023 (€0.11 Mil) to Dec. 2024 (€1.18 Mil) and increased from Dec. 2024 (€1.18 Mil) to Dec. 2025 (€2.66 Mil).

Veraxa Biotech Holding AG Other Current Liabilities Related Terms

Veraxa Biotech Holding AG Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Other Current Liabilities Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Other Current Liabilities
0.11 1.18 2.66

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities 0.11 0.00 1.18 0.90 2.66
FRA:J8L0
13GF Score
Veraxa Biotech Holding AG FRA:J8L0
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €2.66 Mil mean?
Veraxa Biotech Holding AG (FRA:J8L0) has a Other Current Liabilities of €2.66 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Veraxa Biotech Holding AG.
Is Veraxa Biotech Holding AG's Other Current Liabilities too high?
Veraxa Biotech Holding AG's current Other Current Liabilities is €2.66 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Other Current Liabilities compare to TTRX and IRD?
Veraxa Biotech Holding AG's Other Current Liabilities of €2.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Veraxa Biotech Holding AG. Veraxa Biotech Holding AG's current Other Current Liabilities is €2.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (FRA:J8L0) has a current Other Current Liabilities of €2.66 Mil. The current Other Current Liabilities is €2.66 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Veraxa Biotech Holding AG (FRA:J8L0), the current Other Current Liabilities is €2.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges VRXA:USA
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
13GF Score

Get the complete analysis for FRA:J8L0

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price